Professor Pugatch delivered a keynote presentation at the 25th Annual Conference of the Irish Pharmaceutical Healthcare Association (IPHA) at Dublin, Ireland, themed ‘Patient Care, Powered By Innovation’.
In the field of professional boxing, Ireland was and remains a global superpower and a role model. Yet in the field of biopharmaceutical innovation, Ireland does not step into the ring of greats:
- Despite retaining the reputation of a global leader in advances biopharmaceutical manufacturing – with €10 billion invested over the past decade – important opportunities for increasing local research capacity under Horizon 2020 and IMI were missed.
- Ireland’s performance in global indices is mixed – high on employment impact, low on patenting rates and scientific outputs.
- Clinical research levels remain low compared to Ireland’s potential, and corporate biopharma R&D investments follow suit.
- The market access environment is challenging, with low levels of access to innovative treatments and long delays in reimbursement decisions.
Ireland can attain global leadership in both advanced bio-manufacturing as well as biotech innovation. This goal can be achieved by building confidence through constructive industry-government partnerships, enabling the continued public support in local innovative capacity while increasing attractiveness to biomedical FDI.
Looking to the Fourth Industrial Revolution, is it time for Ireland to put on the boxing gloves?Share